Insulin Lispro vs Insulin lispro (Lyumjev)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

Insulin Lispro · Humalog

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01474538 · Phase 3 · completed

The study randomized 122 participants to receive both insulin lispro and insulin aspart in crossover order, with participants, investigators, and outcome assessors masked. Its primary clinical endpoint, HbA1c after 16 weeks, met the prespecified non-inferiority criterion for lispro versus aspart, with the upper confidence limit below the 0.4% margin.

Next expected readout: December 2026 · NCT06251635 (registry estimate)

Reported efficacy

Glycosylated Hemoglobin A1C (HbA1c) at Endpoint (After 16 weeks of each treatment (Periods1 and 2)): Glycosylated Hemoglobin A1C (HbA1c) at Endpoint (After 16 weeks of each treatment (Periods1 and 2)): Insulin Lispro 7.5 percentage of glycosylated hemoglobin (Standard Error 0.12) | Insulin Aspart 7.4 percentage of glycosylated hemoglobin (Standard Error 0.12) (met)

Result source: NCT01474538

Insulin lispro (Lyumjev)

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Partial signal

NCT03214380 · Phase 3 · completed

The study randomized and double-blinded participants to LY900014 or insulin lispro, with 933 enrolled and approximately 336-337 participants in the main comparison arms. The primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a laboratory surrogate rather than a hard clinical endpoint, supporting a moderate evidence grade.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061) (met)

Result source: NCT03952143

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin LisproInsulin lispro (Lyumjev)
HbA1c, change-1.2% vs -1.1%vs Insulin Glargine1.5 mg · wk 26 · n 138NCT01621178
20 other results
  • -1.6% vs -1.4% 1.5 mg · wk 26 · n 273 · Phase 3 · primary NCT01191268
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.6% vs -1.4% 0.75 mg · wk 26 · n 275 · Phase 3 · primary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 345 · Phase 3 · primary NCT02229227
  • -1.7% vs -1.4% wk 26 · n 684 · Phase 3 · primary NCT01468987
  • -1.2% vs -1.3% wk 24 · n 148 · Phase 3 · primary NCT00666718
  • -1.5% vs -1.2% 1.5 mg · wk 52 · n 273 · Phase 3 · secondary NCT01191268
  • -1.4% vs -1.2% 0.75 mg · wk 52 · n 275 · Phase 3 · secondary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1.3% wk 24 · n 179 · Phase 3 · secondary NCT00666718
  • -1.0% vs -1.1% wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9% vs -1.0% wk 12 · n 179 · Phase 3 · secondary NCT00666718
  • -0.9% vs -1.0% wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.7% vs -0.6% wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6% vs -0.5% wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1% vs -0.8% wk 16 · n 131 · Phase 4 · secondary NCT00393705
-0.4% vs -0.4%vs Insulin Lispro (Humalog)wk 26 · n 334NCT03214380
1 other result
  • -0.6% vs -0.6% wk 26 · n 388 · Phase 3 · primary NCT03952143
Body weight, change (kg)-2.8 vs 1.1vs Insulin Glargine1.5 mg · wk 26 · n 140NCT01621178
15 other results
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • -1.9 vs 2.4 wk 26 · n 349 · Phase 3 · secondary NCT02229227
  • -1.9 vs 2.4 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • 1.3 vs 2.2 wk 26 · n 682 · Phase 3 · secondary NCT01468987
  • 1.0 vs 1.2 wk 24 · n 187 · Phase 3 · secondary NCT00666718
  • -2.0 vs 2.1 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.7 vs 1.5 wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9 vs 0.8 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6 vs 0.7 wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • 0.3 vs 0.9 wk 16 · n 116 · Phase 3 · secondary NCT01474538
  • 2.6 vs 2.7 wk 48 · n 138 · Phase 4 · secondary NCT00664534
  • 1.3 vs 0.4 wk 16 · n 126 · Phase 4 · secondary NCT00393705
—Not reported
HbA1c below 7%32.9% vs 29.1%vs Insulin Glargine1.5 mg · wk 52 · n 152NCT01621178
3 other results
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
—Not reported
Fasting plasma glucose, change-2.0 vs -1.5vs Insulin Lispro + Insulin Glarginewk 26 · n 345NCT02229227
4 other results
  • -2.0 vs -1.5 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.8 vs -1.2 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1 vs -0.9 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -1.3 vs -0.8 wk 4 · n 402 · Phase 3 · secondary NCT02229227
—Not reported
3-point MACE (% with event)—Not posted · NCT00551356—Not reported

HbA1c, change

Insulin Lispro
-1.2% vs -1.1%vs Insulin Glargine1.5 mg · wk 26 · n 138NCT01621178
20 other results
  • -1.6% vs -1.4% 1.5 mg · wk 26 · n 273 · Phase 3 · primary NCT01191268
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.6% vs -1.4% 0.75 mg · wk 26 · n 275 · Phase 3 · primary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 345 · Phase 3 · primary NCT02229227
  • -1.7% vs -1.4% wk 26 · n 684 · Phase 3 · primary NCT01468987
  • -1.2% vs -1.3% wk 24 · n 148 · Phase 3 · primary NCT00666718
  • -1.5% vs -1.2% 1.5 mg · wk 52 · n 273 · Phase 3 · secondary NCT01191268
  • -1.4% vs -1.2% 0.75 mg · wk 52 · n 275 · Phase 3 · secondary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1.3% wk 24 · n 179 · Phase 3 · secondary NCT00666718
  • -1.0% vs -1.1% wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9% vs -1.0% wk 12 · n 179 · Phase 3 · secondary NCT00666718
  • -0.9% vs -1.0% wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.7% vs -0.6% wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6% vs -0.5% wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1% vs -0.8% wk 16 · n 131 · Phase 4 · secondary NCT00393705
Insulin lispro (Lyumjev)
-0.4% vs -0.4%vs Insulin Lispro (Humalog)wk 26 · n 334NCT03214380
1 other result
  • -0.6% vs -0.6% wk 26 · n 388 · Phase 3 · primary NCT03952143

Body weight, change (kg)

Insulin Lispro
-2.8 vs 1.1vs Insulin Glargine1.5 mg · wk 26 · n 140NCT01621178
15 other results
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • -1.9 vs 2.4 wk 26 · n 349 · Phase 3 · secondary NCT02229227
  • -1.9 vs 2.4 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • 1.3 vs 2.2 wk 26 · n 682 · Phase 3 · secondary NCT01468987
  • 1.0 vs 1.2 wk 24 · n 187 · Phase 3 · secondary NCT00666718
  • -2.0 vs 2.1 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.7 vs 1.5 wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9 vs 0.8 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6 vs 0.7 wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • 0.3 vs 0.9 wk 16 · n 116 · Phase 3 · secondary NCT01474538
  • 2.6 vs 2.7 wk 48 · n 138 · Phase 4 · secondary NCT00664534
  • 1.3 vs 0.4 wk 16 · n 126 · Phase 4 · secondary NCT00393705
Insulin lispro (Lyumjev)
—Not reported

HbA1c below 7%

Insulin Lispro
32.9% vs 29.1%vs Insulin Glargine1.5 mg · wk 52 · n 152NCT01621178
3 other results
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
Insulin lispro (Lyumjev)
—Not reported

Fasting plasma glucose, change

Insulin Lispro
-2.0 vs -1.5vs Insulin Lispro + Insulin Glarginewk 26 · n 345NCT02229227
4 other results
  • -2.0 vs -1.5 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.8 vs -1.2 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1 vs -0.9 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -1.3 vs -0.8 wk 4 · n 402 · Phase 3 · secondary NCT02229227
Insulin lispro (Lyumjev)
—Not reported

3-point MACE (% with event)

Insulin Lispro
—Not posted · NCT00551356
Insulin lispro (Lyumjev)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Insulin Lispro: 5 of 5 rows · Insulin lispro (Lyumjev): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin Lispro
Rows use multiple source trials
Insulin lispro (Lyumjev)
Rows use multiple source trials
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.48% (n=115)a,b,c,d,e
NCT01194258 · Phase 2 · registry result, not featured evidence
show 1 more dose
-0.46% (n=115)
NCT01194258 · Phase 2 · registry result, not featured evidence
-0.44% (n=167) @ 12wkb,c,d,e
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Dropout rate
—f
NCT01474538 · Phase 3
show 18 more results
19.3%
NCT00664534 · Phase 4 · registry result, not featured evidence
15.2%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
4.7%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
12.7%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
—1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
—0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
10.3%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
19.7%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
18.8%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
—Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
9.6%ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
—Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
—Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
—
NCT02197520 · Phase 1 · registry result, not featured evidence
11.1%
NCT05893797 · Phase na · registry result, not featured evidence
—g
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
—LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
—LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—f
NCT01474538 · Phase 3
show 18 more results
1.8%
NCT00664534 · Phase 4 · registry result, not featured evidence
0%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
0.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
3.5%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
—1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
—0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
1.7%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
7.1%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
4.4%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
—Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
0.5%ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
—Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
—Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
—
NCT02197520 · Phase 1 · registry result, not featured evidence
2.8%
NCT05893797 · Phase na · registry result, not featured evidence
—g
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.7%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
—LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
—LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Serious AEs
12.7%f
NCT01474538 · Phase 3
show 18 more results
4.1%
NCT00664534 · Phase 4 · registry result, not featured evidence
2.2%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
6.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
5.8%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
21.4%1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
25.3%0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
11.4%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
9.2%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
15.7%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
4.8%Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
7.5%Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
0%Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
0%Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
4.5%Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
0%Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
0%
NCT02197520 · Phase 1 · registry result, not featured evidence
8.3%
NCT05893797 · Phase na · registry result, not featured evidence
7.7%g
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
8.4%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.7%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
0%LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
0%LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
f
nasopharyngitis 4.2%
nausea 4.2%
fatigue 3.4%
NCT01474538 · Phase 3
show 17 more results
pyrexia 3.6%
neuropathy peripheral 3%
diarrhoea 2.4%
NCT00664534 · Phase 4 · registry result, not featured evidence
nasopharyngitis 4.3%
bronchitis 2.2%
arthralgia 1.4%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 6.3%
influenza 3.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nausea 9.3%
diarrhoea 7.8%
viral upper respiratory tract infection 6.3%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
blood creatinine increased 38.5%
nausea 19.8%
diarrhoea 16.1%
NCT01621178 · Phase 3 · registry result, not featured evidence
0.75 mg
blood creatinine increased 37.4%
diarrhoea 15.8%
nausea 14.2%
NCT01621178 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.1%
upper respiratory tract infection 4.2%
diarrhoea 3.5%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
nausea 25.8%
diarrhea 14.9%
vomiting 11.9%
NCT01191268 · Phase 3 · registry result, not featured evidence
0.75 mg
nausea 17.7%
diarrhea 11.6%
vomiting 10.6%
NCT01191268 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.4%
headache 5.9%
diarrhoea 4.3%
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 5.3%
headache 4.8%
viral infection 3.7%
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 6.8%
headache 3.4%
influenza 3.4%
NCT01194258 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 11.9%
diarrhoea 8.5%
nasopharyngitis 5.1%
NCT01194258 · Phase 2 · registry result, not featured evidence
abdominal pain 4.5%
diarrhoea 4.5%
injection site pain 4.5%
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
headache 13.6%
nausea 9.1%
abdominal pain 4.5%
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
catheter site related reaction 12.5%
upper respiratory tract infection 12.5%
urinary tract infection 12.5%
NCT02197520 · Phase 1 · registry result, not featured evidence
covid-19 8.3%
bronchitis 5.6%
dermatitis allergic 5.6%
NCT05893797 · Phase na · registry result, not featured evidence
g
nasopharyngitis 14%
upper respiratory tract infection 8%
diarrhoea 3.3%
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 15 more results
upper respiratory tract infection 5.3%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
injection site reaction 5.6%
NCT03341312 · Phase 1 · registry result, not featured evidence
injection site reaction 2.9%
NCT03341312 · Phase 1 · registry result, not featured evidence
15 U
headache 10%
nausea 5%
injection site reaction 2.5%
NCT03286751 · Phase 1 · registry result, not featured evidence
30 U
headache 14.6%
injection site reaction 14.6%
nausea 7.3%
NCT03286751 · Phase 1 · registry result, not featured evidence
7 U
headache 15%
injection site reaction 2.5%
nausea 2.5%
NCT03286751 · Phase 1 · registry result, not featured evidence
15 U
headache 5.3%
vessel puncture site thrombosis 5.3%
NCT03305822 · Phase 1 · registry result, not featured evidence
15 U
infusion site pain 12%
catheter site bruise 8%
vessel puncture site bruise 8%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
injection site pain 11.5%
application site erythema 7.7%
catheter site bruise 7.7%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
catheter site pain 10.7%
catheter site swelling 7.1%
application site erythema 3.6%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
catheter site bruise 7.7%
infusion site erythema 7.7%
infusion site swelling 7.7%
NCT03232983 · Phase 1 · registry result, not featured evidence
headache 6.7%
back pain 0%
thrombophlebitis 0%
NCT02703337 · Phase 1 · registry result, not featured evidence
back pain 0%
headache 0%
thrombophlebitis 0%
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
thrombophlebitis 6.9%
back pain 0%
headache 0%
NCT02703337 · Phase 1 · registry result, not featured evidence
thrombophlebitis 10.3%
back pain 0%
headache 0%
NCT02703337 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eThe assessment timepoint is not available for both results.
  6. fPopulation comparability has not been reviewed for 18 of these studies.
  7. gPopulation comparability has not been reviewed for 14 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin Lispro

HbA1c 7.5% (n=112) vs 7.4% (n=111) Insulin Aspart @ 16wk
absolute value · percentage points
NCT01474538 · Phase 3
show 6 more results
7.4% (n=108) vs 7.55% (n=98) Glargine @ 48wk
NCT00664534 · Phase 4 · registry result, not featured evidence
7.62% (n=158) vs 7.57% (n=163) Glargine @ 16wk
NCT00664534 · Phase 4 · registry result, not featured evidence
7.46% (n=158) vs 7.43% (n=163) Glargine @ 32wk
NCT00664534 · Phase 4 · registry result, not featured evidence
7.33% (n=158) vs 7.4% (n=163) Glargine @ 48wk
NCT00664534 · Phase 4 · registry result, not featured evidence
7.71% (n=131) vs 7.84% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
6.76% (n=684) vs 6.97% (n=672) Insulin Glargine + Insulin Lispro @ 26wk
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
Weight -2.81 vs 1.11 Insulin Glargine kg @ 26wk1.5 mg
absolute change · kg
NCT01621178 · Phase 3 · registry result, not featured evidence
show 15 more results
-2.66 vs 1.57 Insulin Glargine kg @ 52wk1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
-2.02 vs 1.11 Insulin Glargine kg @ 26wk0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
-1.71 vs 1.57 Insulin Glargine kg @ 52wk0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
0.31 vs 0.89 Insulin Aspart kg @ 16wk
NCT01474538 · Phase 3
2.61 vs 2.7 Glargine kg @ 48wk
NCT00664534 · Phase 4 · registry result, not featured evidence
1.3 vs 0.4 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM kg @ 16wk
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
2.67 vs 2.53 Insulin Glargine kg @ 26wk
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-1.95 vs 2.43 Insulin Lispro + Insulin Glargine kg @ 26wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-0.55 vs 0.66 Insulin Lispro + Insulin Glargine kg @ 4wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-0.95 vs 0.85 Insulin Lispro + Insulin Glargine kg @ 5wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-1.71 vs 1.46 Insulin Lispro + Insulin Glargine kg @ 10wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-1.96 vs 2.06 Insulin Lispro + Insulin Glargine kg @ 18wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
-1.95 vs 2.43 Insulin Lispro + Insulin Glargine kg @ 26wk
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
1.25 vs 2.21 Insulin Glargine + Insulin Lispro kg @ 26wk
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
1.03 vs 1.19 Glargine kg @ 24wk
NCT00666718 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 30.3% (n=158) vs 24.2% (n=163) Glargine @ 16wk
responder rate · % of participants
Week 16 HbA1c <=7.0% (n=157, n=155)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 18.7% (n=158) vs 14.6% (n=163) Glargine @ 16wk
responder rate · % of participants
Week 16 HbA1c <=6.5% (n=157, n=155)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 37.6% (n=158) vs 32.1% (n=163) Glargine @ 32wk
responder rate · % of participants
Week 32 HbA1c <=7.0% (n=137, n=141)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 20.6% (n=158) vs 19% (n=163) Glargine @ 32wk
responder rate · % of participants
Week 32 HbA1c <=6.5% (n=137, n=141)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 48.2% (n=158) vs 36.2% (n=163) Glargine @ 48wk
responder rate · % of participants
Week 48 HbA1c <=7.0% (n=130, n=137)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 24.8% (n=158) vs 18.5% (n=163) Glargine @ 48wk
responder rate · % of participants
Week 48 HbA1c <=6.5% (n=130, n=137)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 21.4% (n=131) vs 18.5% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
responder rate · % of participants
HbA1c <7%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
A1C Less Than 6 5 11.5% (n=131) vs 6.7% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
responder rate · % of participants
HbA1c ≤6.5%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
PP 2 h Glucose mg/dL 163.4 vs 178.2 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM mg @ 16wk
absolute value · mg
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
PPG 2 h Excursion mg/dL 17 vs 36.1 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM mg @ 16wk
absolute value · mg
NCT00393705 · Phase 4 · registry result, not featured evidence · combination

+ 48 further endpoints in the CSV export.

Insulin lispro (Lyumjev)

HbA1c 7.0 or Less 58.2% (n=316) vs 52.5% (n=320) Insulin Lispro (Humalog) @ 26wk
event count · % of participants
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 184 Participants as posted
PPG 1H Excursion mg/dL 86.2 vs 100.8 Insulin Lispro (Humalog) mg @ 26wk
absolute value · mg
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
PPG 2 h Excursion mg/dL 6.18 vs 7.39 Insulin Lispro (Humalog) mmol/L @ 26wk
absolute value · mmol/L
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from 111.4 mg/dL as posted
HbA1c Less Than 7% 46.65% (n=358) vs 44.5% (n=191) Insulin Lispro (Humalog) @ 26wk
responder rate · % of participants
HbA1c < 7%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c 6 5 or Less 27.93% (n=358) vs 27.23% (n=191) Insulin Lispro (Humalog) @ 26wk
responder rate · % of participants
HbA1c ≤ 6.5%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time in Range Daytime 3.8 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time in Range 24 h 3.3 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Below 54 0 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above 180 -3.4 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-Hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above 2.50 -1.07 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-Hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Postprandial iAUC 0 1H -2.46 mg @ 12wk
absolute change · mg
No placebo or comparator arm
Overall - across meals
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Postprandial iAUC 0-2h -8.8 mg @ 12wk
absolute change · mg
No placebo or comparator arm
Overall - across meals
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3

+ 6 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin Lispro's landscape · Insulin lispro (Lyumjev)'s landscape